Bonus BioGroup
Press Room

Press Releases 2021

Press Releases 2021

Following safety and efficacy preclinical results of the unique drug product MesenCure, a therapy specifically developed by Bonus BioGroup for the life-threatening acute respiratory distress in coronavirus (Covid-19) patients and pneumonia;


Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products.

Following a previous announcement, dated July 22, 2020 regarding the Company’s development of an advanced version of the drug product MesenCure, specifically developed to treat the life-threatening acute respiratory distress in coronavirus (Covid-19) patients and pneumonia, and subsequent to additional safety and efficacy preclinical results obtained, Bonus BioGroup is pleased to announce that on January 18, 2021, it has received the necessary approvals from the Israeli Ministry of Health and from Rambam Health Care Campus, Haifa, to conduct a phase I/II clinical trial to evaluate the safety and efficacy of MesenCure in the treatment of Covid-19 patients (hereinafter: “the clinical trial for the treatment of respiratory distress”).

FOR MORE INVESTOR RELATION INFORMATION

Press Release, Announcements publication and more

Bonus BioGroup

Image

 

Terms of UsePrivacy Policy | Login        

© 2021 Bonus BioGroup Ltd. All Rights Reserved. Designed By Netron Israel Ltd.